Objective·To explore the value of miR-499 expression levels in the serum of patients with acute coronary syndrome(ACS)in predicting the severity of coronary artery disease.Methods·Seventy-four patients with ACS admitted to Xinhua Hospital,Shanghai Jiao Tong University School of Medicine were included and divided into a mild group of 30 cases,a moderate group of 21 cases,and a severe group of 23 cases according to the Gensini score.Real-time quantitative polymerase chain reaction(qPCR)technology was used to detect the expression level of serum miR-499,while troponin(cTnI),creatine kinase isoenzyme(CK-MB),myoglobin(Mb),brain natriuretic peptide(BNP),left ventricular ejection fraction(LVEF),and other laboratory indicators were measured.Spearman correlation analysis was used to analyze the correlation between the expression level of miR-499 and Gensini score,as well as the number of vessel branches in coronary artery disease.The evaluation value of miR-499 in assessing the severity of coronary artery disease was analyzed by using receiver operating characteristic(ROC)curve.Results·The expression level of miR-499 increased with the severity of coronary artery disease(P=0.000).The expression level of miR-499 was positively correlated with Gensini score and cTnI(r=0.331,r=0.143,P＜0.05),respectively,but not with LVEF(P＞0.05),while Gensini score was not correlated with cTnI and LVEF(P＞0.05).ROC analysis showed that the AUC of miR-499 for assessing the severity of coronary artery disease was 0.802(95％CI 0.698-0.906),with sensitivity of 65.2％and specificity of 80.4％.The expression level of miR-499 increased with the increase of the number of coronary artery lesions,and was positively correlated with the number of coronary artery lesions(r=0.368,P＜0.05).Conclusion·The expression level of miR-499 in the serum of ACS patients is correlated with the severity and number of coronary artery lesions,which has a certain evaluation value in evaluating the severity of coronary artery lesions.

Objective:To evaluate the post-marketing safety and immunogenicity of a 23-valent pneumococcal polysaccharide vaccine (PPV23).Methods:From September 2020 to June 2021, a clinical trial of single-dose PPV23 was conducted in people ≥3 years old in Centers for Disease Control and Prevention of Guizhou, Hunan and Fujian provinces. Blood samples were collects from the subjects before and 30 d after vaccination. ELISA was used to quantitatively detect IgG antibodies against capsular polysaccharides of 23 Streptococcus pneumoniae serotypes in serum samples. The adverse events (AEs) were monitored within 7 d after vaccination. Results:A total of 409 subjects were enrolled and included in safety analysis. Except for one with antibody level inversion, the other 408 participants were included in immunogenicity analysis. The levels of antibodies against the 23 Streptococcus pneumoniae serotypes were all increased after vaccination by an average of 4.24 folds. The two-fold growth rates of the antibodies ranged from 51.72% to 96.81% with a total two-fold growth rate of 78.59%. The overall rate of AEs was 27.14% (111/409). Local AEs were mainly pain, induration, redness and swollen. No serious adverse events related to vaccination occurred. Conclusions:This study preliminarily demonstrated the good immunogenicity and safety of PPV23 vaccine.